Back to Newsroom

Immunexpress Appoints Dr. Bea Arnold to Board of Directors

SEATTLE, Sept. 29, 2015 – Immunexpress, Inc., a molecular diagnostic company committed to improving outcomes for suspected sepsis patients, today announced that Dr. Bea Arnold has joined the Company’s Board of Directors.

“We are delighted to welcome Dr. Arnold to our Board of the Directors,” said Roslyn Brandon, President and CEO of Immunexpress. “Debiopharm is a Series A and B investor in Immunexpress and a supportive collaborator. Dr. Arnold’s experience in diagnostics and business development will be valuable as we advance the SeptiCyte® technology through regulatory clearance and into the market.”

Click here to read more